International Registry for Men with Advanced Prostate Cancer (IRONMAN)
IRONMAN is an international study focused on improving outcomes for men with advanced prostate cancer. Study participants had a diagnosis of prostate cancer, were at least 21 years old, and were recruited from over 100 sites in 16 countries, namely Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, United Kingdom, and United States of America. As of 2023, over 3,000 participants have completed the baseline assessment. Follow-up assessments are conducted every three months for the first two years, and then every six months thereafter for at least 5 years.
Study design
Registry
Number of participants at first data collection
3,092 (participants as of 2023)
Recruitment is ongoing
Age at first data collection
≥ 21 years (participants)
Participant year of birth
Varied (participants)
Participant sex
Male
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2017
Primary Institutions
Movember Foundation (Third Sector, United Kingdom)
Prostate Cancer Clinical Trials Consortium (PCCTC) (Academic, United States of America)
Yale University (Academic, United States of America)
Profile paper DOI
Funders
Amgen Inc. (Industry, United States of America)
Astellas Pharma Inc. (アステラス製薬株式会社) (Industry, Japan)
AstraZeneca (Industry, United Kingdom)
Bayer UK (Industry, United Kingdom)
Distinguished Gentleman's Ride (Third Sector, Australia)
Ongoing?
Yes
Data types collected
- Activity log (e.g. food, sleep, exercise)
- Interview – face-to-face
- Interview – phone
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- Secondary data
- Self-completed questionnaire – online
- None
- None
- Healthcare data
Engagement
Keywords
